ARTICLE | Financial News

MD Anderson, Theraclone launch OncoResponse

October 7, 2015 1:19 AM UTC

The University of Texas MD Anderson Cancer Center (Houston, Texas) and Theraclone Sciences Inc. (Seattle, Wash.) jointly launched cancer immunotherapy company OncoResponse Inc. (Houston, Texas). The newco closed a $9.5 million series A round co-led by Arch Venture Partners; Canaan Partners; and MD Anderson. Rice University and Alexandria Real Estate Equities also participated.

OncoResponse will use Theraclone's I-STAR antibody discovery platform to identify antibodies from exceptional responders to immunotherapy. MD Anderson will provide the company with samples and physiologic, prognostic and genotypic data from exceptional responders. ...